Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Godefridus J. Peters

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5447-2877; OpenAlex author ID A5035296183. Sources: OpenAlex.

Their work

Papers
36 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
71
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 6 papers · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 36

  1. Eph receptors in pancreatic cancer: Biological roles and clinical implications. Co-author DOI 10.1016/j.critrevonc.2026.105299↗
  2. Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models. Co-author DOI 10.1002/cmdc.202500448↗
  3. Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer. Co-author DOI 10.1080/15257770.2024.2319215↗
  4. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Co-author DOI 10.7150/ijbs.92671↗
  5. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s10555-023-10127-w↗
  6. The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells. Last author DOI 10.1080/15257770.2022.2031215↗
  7. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15592294.2021.1916697↗
  8. GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.drup.2021.100779↗
  9. SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. Co-author DOI 10.20517/cdr.2021.61↗
  10. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/cancers13174389↗
  11. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells. Co-author DOI 10.3390/molecules27010019↗
  12. Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2020.112088↗
  13. Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models. Co-author DOI 10.1186/s40164-020-00176-0↗
  14. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Up… Co-author DOI 10.3390/cancers12113206↗
  15. 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/molecules25020329↗
  16. Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. Last author DOI 10.21873/anticanres.13508↗
  17. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivative… Co-author DOI 10.21873/anticanres.13509↗
  18. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Co-author DOI 10.3390/cancers11050638↗
  19. CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage. Co-author DOI 10.3390/molecules24244445↗
  20. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.drup.2017.07.001↗
  21. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Last author DOI 10.1016/j.semcancer.2017.04.006↗
  22. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. Co-author DOI 10.1186/s13045-016-0371-1↗
  23. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. Last author DOI 10.1007/978-1-4939-3347-1_10↗
  24. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i31.6987↗
  25. Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.semcancer.2015.09.011↗
  26. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Co-author DOI 10.1038/bjc.2013.681↗
  27. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Co-author DOI 10.1080/15257770.2014.891741↗
  28. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. Co-author DOI 10.1093/jnci/djt346↗
  29. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0108057↗
  30. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.2104↗
  31. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Co-author DOI 10.2217/pgs.13.225↗
  32. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Co-author DOI 10.1002/ijc.28078↗
  33. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Co-author DOI 10.2174/138161213804547312↗
  34. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Co-author DOI 10.1158/1535-7163.mct-12-0037↗
  35. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. Last author DOI 10.1371/journal.pone.0049145↗
  36. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Co-author DOI 10.2217/pgs.11.109↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 36 shared papers, 2011–2026 · strength 3.79
  2. Patrizia Diana · 10 shared papers, 2019–2025 · strength 1.40
  3. Daniela Carbone · 10 shared papers, 2019–2025 · strength 1.35
  4. Stella Cascioferro · 8 shared papers, 2019–2025 · strength 1.05
  5. Barbara Parrino · 7 shared papers, 2019–2025 · strength 0.89
  6. Niccola Funel · 16 shared papers, 2011–2020 · strength 0.85
  7. Btissame El Hassouni · 7 shared papers, 2019–2024 · strength 0.85
  8. Camilla Pecoraro · 5 shared papers, 2021–2025 · strength 0.77
  9. Amir Avan · 12 shared papers, 2012–2021 · strength 0.58
  10. Amir Avan · 3 shared papers, 2021–2024 · strength 0.55
  11. Tessa Y. S. Le Large · 4 shared papers, 2014–2026 · strength 0.52
  12. Mahrou Vahabi · 2 shared papers, 2023–2024 · strength 0.52
  13. Geng Xu · 2 shared papers, 2024–2025 · strength 0.52
  14. Geert Kazemier M · 3 shared papers, 2016–2026 · strength 0.48
  15. Ornella Randazzo · 3 shared papers, 2020–2022 · strength 0.38
  16. Karlijn A. van de Langerijt · 1 shared paper, 2026 · strength 0.36
  17. I Gede Putu Supadmanaba · 2 shared papers, 2022–2024 · strength 0.33
  18. Giovanna Li Petri · 3 shared papers, 2019–2020 · strength 0.29
  19. Mina Maftouh · 7 shared papers, 2013–2017 · strength 0.29
  20. Omidreza Firuzi · 3 shared papers, 2017–2020 · strength 0.29
  21. Adam Enver Frampton · 4 shared papers, 2013–2020 · strength 0.26
  22. Ugo Boggi · 6 shared papers, 2012–2017 · strength 0.23
  23. Ingrid Garajová · 3 shared papers, 2016–2020 · strength 0.23
  24. Alessandro Gregori · 2 shared papers, 2020 · strength 0.23
  25. Rocco Sciarrillo · 2 shared papers, 2014–2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.